Ironorefan
Oct 12, 5:17 PM
$CAPR the troll raising concerns about safety obviously can’t read or doesn’t understand tables. Per the lancet -
594 treatment emergent adverse events were reported by month 12 (table 3; table 4; appendix pp 16–24) with incidences for deramiocel to placebo of 94·3% to 82·7% with risk-ratio of 1·14 (95% CI 0·99–1·31). 98% of adverse events were mild to moderate in severity and 23% were related to hypersensitivity. Hypersensitivity reactions (appendix p 15) were more frequent among deramiocel-treated participants (41·5%) versus placebo (15·4%). The most frequently reported adverse events (≥10% incidence) were headaches (35·2%), cough (15·2%), pyrexia (14·3%), nausea (12·4%), and tachycardia (12·4%), which predominantly resolved within 24–48 h. More placebo recipients experienced at least one grade 3 or higher treatment-emergent adverse event. Two participants had treatment-related serious adverse events (appendix p 25).
0 replies
